인도의 수탁 제조 기관(CMO) 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the India contract manufacturing organization market size was valued at USD 25.81 billion in 2025 and estimated to grow from USD 29.53 billion in 2026 to reach USD 57.94 billion by 2031, at a CAGR of 14.43% during the forecast period (2026-2031).

This report is Segmented by Service Type (API and Intermediates, Finished Dose), Molecule Type (Small Molecules, and Large Molecules/Biologics), End-User (Big Pharma, Mid-Size Pharma, and Virtual/Start-ups), Therapeutic Area (Oncology, Cardiovascular, and More), and Manufacturing Scale (Pre-Clinical, Clinical, Commercial). The Market Forecasts are Provided in Terms of Value (USD).

India Contract Manufacturing Organization (CMO) Market Trends and Insights

Growing Biologics Outsourcing Pipeline

India is securing a rising share of global biologics contracts as sponsors pursue lower cost locations without compromising quality. Aurigene opened a 70,000-square-foot monoclonal antibody plant in Genome Valley in 2025, illustrating the industry's pivot toward mammalian cell culture expertise. Specialized facilities command premium pricing because barriers to entry remain high, yet India still undercuts Western cost structures. CDSCO Schedule M upgrades ensure alignment with U.S. FDA and EMA standards, removing a key procurement hurdle for multinational firms. As a result, contract values for biologics projects are lengthening, and repeat orders are climbing. Sustained double-digit growth is therefore expected for this capability set through 2030.

Strong Demand for Complex Injectables

Sterile manufacturing complexity and limited global capacity are funneling injectable assignments toward Indian CDMOs. Sanofi's USD 437 million Hyderabad expansion focuses on pre-filled syringes and lyophilized oncology products, underscoring confidence in local expertise. Domestic players are simultaneously scaling fermentation suites for high-potency intermediates. Premium pricing persists because safety regulations mandate rigorous environmental controls, while lead times from alternate Asian hubs remain long. The segment meshes with global moves toward personalized medicine, where complex delivery systems are essential. These conditions maintain a high-margin outlook over the next two years.

Volatile Raw-Material Prices Linked to China Supply

China supplies more than 70% of India's key starting materials, and 2024 environmental clampdowns raised intermediate costs by 20-30%. Margin compression forces CDMOs to renegotiate long-term contracts, straining client relationships. Although PLI parks promise domestic feedstock, scale-up will take multiple years. Hedging strategies and dual sourcing add overheads, weighing on near-term profitability. Sponsors may also withhold multi-year awards until price visibility improves.

Other drivers and restraints analyzed in the detailed report include:

1. Capacity Expansions by Global Big-Pharma in India
2. AI-Enabled Process-Development Efficiencies
3. Rising FDA Warning Letters to Indian Sites

For complete list of drivers and restraints, kindly check the Table Of Contents.

List of Companies Covered in this Report:

1. Divi's Laboratories Limited
2. Dr. Reddy's Laboratories Limited
3. Sun Pharmaceutical Industries Limited
4. Aurobindo Pharma Limited
5. Zydus Lifesciences Limited (Cadila Healthcare)
6. Cipla Limited
7. Lupin Limited
8. Jubilant Pharmova Limited
9. Biocon Limited
10. MSN Laboratories Private Limited
11. Viatris Inc. (Mylan Laboratories Ltd.)
12. Akums Drugs and Pharmaceuticals Limited
13. Wockhardt Limited
14. Theon Pharmaceuticals Limited
15. BDR Pharmaceuticals International Private Limited
16. Ciron Drugs & Pharmaceuticals Private Limited
17. Medipaams India Private Limited
18. Bharat Biotech International Limited
19. Strides Pharma Science Limited
20. Alkem Laboratories Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing biologics outsourcing pipeline
  • 4.2.2 Strong demand for complex injectables
  • 4.2.3 Capacity expansions by global big-pharma in India
  • 4.2.4 Government PLI (Production-Linked Incentive) schemes for APIs
  • 4.2.5 Venture funding in CDMO start-ups
  • 4.2.6 AI-enabled process-development efficiencies
• 4.3 Market Restraints
  • 4.3.1 Volatile raw-material prices linked to China supply
  • 4.3.2 Rising FDA warning letters to Indian sites
  • 4.3.3 Skilled-talent attrition in key clusters
  • 4.3.4 Emerging capacity glut in oral-solid dosages
• 4.4 Industry Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry
• 4.8 Impact of Macroeconomic Factors on the Market

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Service Type
  • 5.1.1 API and Intermediates
  • 5.1.2 Finished Dose
    • 5.1.2.1 Solids
    • 5.1.2.2 Liquids
    • 5.1.2.3 Semi-solids and Injectables
• 5.2 By Molecule Type
  • 5.2.1 Small Molecules
  • 5.2.2 Large Molecules / Biologics
• 5.3 By End-user
  • 5.3.1 Big Pharma
  • 5.3.2 Mid-Size Pharma
  • 5.3.3 Virtual / Start-ups
• 5.4 By Therapeutic Area
  • 5.4.1 Oncology
  • 5.4.2 Cardiovascular
  • 5.4.3 Anti-infectives
  • 5.4.4 Central Nervous System (CNS)
  • 5.4.5 Other Therapeutic Areas
• 5.5 By Manufacturing Scale
  • 5.5.1 Pre-clinical
  • 5.5.2 Clinical
  • 5.5.3 Commercial

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.4.1 Divi's Laboratories Limited
  • 6.4.2 Dr. Reddy's Laboratories Limited
  • 6.4.3 Sun Pharmaceutical Industries Limited
  • 6.4.4 Aurobindo Pharma Limited
  • 6.4.5 Zydus Lifesciences Limited (Cadila Healthcare)
  • 6.4.6 Cipla Limited
  • 6.4.7 Lupin Limited
  • 6.4.8 Jubilant Pharmova Limited
  • 6.4.9 Biocon Limited
  • 6.4.10 MSN Laboratories Private Limited
  • 6.4.11 Viatris Inc. (Mylan Laboratories Ltd.)
  • 6.4.12 Akums Drugs and Pharmaceuticals Limited
  • 6.4.13 Wockhardt Limited
  • 6.4.14 Theon Pharmaceuticals Limited
  • 6.4.15 BDR Pharmaceuticals International Private Limited
  • 6.4.16 Ciron Drugs & Pharmaceuticals Private Limited
  • 6.4.17 Medipaams India Private Limited
  • 6.4.18 Bharat Biotech International Limited
  • 6.4.19 Strides Pharma Science Limited
  • 6.4.20 Alkem Laboratories Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment